Abstract |
Anti-inflammatory treatment could be expected to show positive effects in the subgroup of psychiatric patients who show signs of inflammation, i.e. an increase in proinflammatory cytokines and PGE2. Cyclooxygenase-2 (COX-2) not only reduces the levels of proinflammatory cytokines, but also affects glutamatergic neurotransmission and tryptophan/ kynurenine metabolism. In the meantime, several studies have been performed with the COX-2 inhibitor celecoxib in schizophrenia; the studies found a therapeutic effect, mainly in the early stages of the disorder. We were able to demonstrate a statistically significant therapeutic effect of celecoxib on depressive symptoms in a study in patients with major depression (MD). Another study in fifty patients with MD also showed a statistically significant better outcome with celecoxib. This paper will discuss immune-based therapeutic approaches in both schizophrenia and depression.
|
Authors | Norbert Müller |
Journal | Psychiatria Danubina
(Psychiatr Danub)
Vol. 25
Issue 3
Pg. 292-8
(Sep 2013)
ISSN: 0353-5053 [Print] Croatia |
PMID | 24048400
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Chemical References |
- Anti-Inflammatory Agents
- Cyclooxygenase 2 Inhibitors
|
Topics |
- Anti-Inflammatory Agents
(therapeutic use)
- Cyclooxygenase 2 Inhibitors
(therapeutic use)
- Depressive Disorder, Major
(drug therapy)
- Humans
- Schizophrenia
(drug therapy)
|